Cargando…
Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment since their introduction ∼15 years ago. However, these monoclonal antibodies are associated with immune-related adverse events that can also affect the kidney, resulting in acute kidney injury (AKI), which is most commonly due...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087122/ https://www.ncbi.nlm.nih.gov/pubmed/33970161 http://dx.doi.org/10.1093/ckj/sfab052 |